Evidence map›Paper›PMID 27409564›Full record

ArticleRadiology2016

Hepatic Thermal Ablation: Effect of Device and Heating Parameters on Local Tissue Reactions and Distant Tumor Growth.

Erik Velez, S Nahum Goldberg, Gaurav Kumar, Yuanguo Wang, Svetlana Gourevitch, Jacob Sosna, Tyler Moon, Christopher L Brace, Muneeb Ahmed

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 101 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Frontiers in immunology · 2023
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Erik VelezFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
S Nahum GoldbergFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Gaurav KumarFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Yuanguo WangFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Svetlana GourevitchFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Jacob SosnaFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Tyler MoonFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Christopher L BraceFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Muneeb AhmedFrom the Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215 (E.V., S.N.G., G.K., Y.W., J.S., M.A.); Division of Image-guided Therapy and Interventional Oncology, Department of Radiology (S.N.G., J.S.), and Goldyne Savad Institute of Gene Therapy (S.G.), Hadassah Hebrew University Hospital, Jerusalem, Israel; and Departments of Radiology and Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis (T.M., C.B.).
Beth Israel Deaconess Medical Center · USHadassah Medical Center · ILUniversity of Wisconsin–Madison · US

Funding

Physico-Chemical Nanocharacterization CoreU54CA151881 · NCI · NORTHEASTERN UNIVERSITY · PI TORCHILIN, VLADIMIR P · 2010 to 2014
$12.4M
NCI NIH HHS U54 CA151881
6 · The paper itself

Abstract

Purpose To determine whether variable hepatic microwave ablation (MWA) can induce local inflammation and distant pro-oncogenic effects compared with hepatic radiofrequency ablation (RFA) in an animal model. Materials and Methods In this institutional Animal Care and Use Committee-approved study, F344 rats (150 gm, n = 96) with subcutaneous R3230 breast adenocarcinoma tumors had normal non-tumor-bearing liver treated with RFA (70°C × 5 minutes), rapid higher-power MWA (20 W × 15 seconds), slower lower-power MWA (5 W × 2 minutes), or a sham procedure (needle placement without energy) and were sacrificed at 6 hours to 7 days (four time points; six animals per arm per time point). Ablation settings produced 11.4 mm ± 0.8 of coagulation for all groups. Distant tumor growth rates were determined to 7 days after treatment. Liver heat shock protein (HSP) 70 levels (at 72 hours) and macrophages (CD68 at 7 days), tumor proliferative indexes (Ki-67 and CD34 at 7 days), and serum and tissue levels of interleukin 6 (IL-6) at 6 hours, hepatocyte growth factor (HGF) at 72 hours, and vascular endothelial growth factor (VEGF) at 72 hours after ablation were assessed. All data were expressed as means ± standard deviations and were compared by using two-tailed t tests and analysis of variance for selected group comparisons. Linear regression analysis of tumor growth curves was used to determine pre- and posttreatment growth curves on a per-tumor basis. Results At 7 days, hepatic ablations with 5-W MWA and RFA increased distant tumor size compared with 20-W MWA and the sham procedure (5-W MWA: 16.3 mm ± 1.1 and RFA: 16.3 mm ± 0.9 vs sham: 13.6 mm ± 1.3, P < .01, and 20-W MWA: 14.6 mm ± 0.9, P < .05). RFA and 5-W MWA increased postablation tumor growth rates compared with the 20-W MWA and sham arms (preablation growth rates range for all arms: 0.60-0.64 mm/d; postablation: RFA: 0.91 mm/d ± 0.11, 5-W MWA: 0.91 mm/d ± 0.14, P < .01 vs pretreatment; 20-W MWA: 0.69 mm/d ± 0.07, sham: 0.56 mm/d ± 1.15; P = .48 and .65, respectively). Tumor proliferation (Ki-67 percentage) was increased for 5-W MWA (82% ± 5) and RFA (79% ± 5), followed by 20-W MWA (65% ± 2), compared with sham (49% ± 5, P < .01). Likewise, distant tumor microvascular density was greater for 5-W MWA and RFA (P < .01 vs 20-W MWA and sham). Lower-energy MWA and RFA also resulted in increased HSP 70 expression and macrophages in the periablational rim (P < .05). Last, IL-6, HGF, and VEGF elevations were seen in 5-W MWA and RFA compared with 20-W MWA and sham (P < .05). Conclusion Although hepatic MWA can incite periablational inflammation and increased distant tumor growth similar to RFA in an animal tumor model, higher-power, faster heating protocols may potentially mitigate such undesired effects.

Indexed as

Neoplasm SeedingAdenocarcinomaAnimalsCatheter AblationDisease Models, AnimalFemaleHepatocyte Growth FactorHyperthermia, InducedInflammationInterleukin-6Ki-67 AntigenLiverMacrophagesMammary Neoplasms, ExperimentalMicrowavesNeoplasm MetastasisHepatocyte Growth FactorInterleukin-6Ki-67 AntigenVascular Endothelial Growth Factor A

Identifiers

PMID27409564
PMCPMC5131835
OpenAlexW2469003638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.